- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
On Tuesday, Halozyme Therapeutics Inc (HALO:NSQ) closed at 51.30, -3.61% below its 52-week high of 53.22, set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 51.95 |
---|---|
High | 52.11 |
Low | 50.68 |
Bid | 50.05 |
Offer | 51.78 |
Previous close | 51.30 |
Average volume | 1.49m |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 21.22 |
Market cap | 6.53bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼